Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

TherapeuticsMD (TXMD) Divestments (2022)

TherapeuticsMD filings provide 2 years of Divestments readings, the most recent being $223.8 million for Q4 2022.

On a quarterly basis, Divestments changed N/A to $223.8 million in Q4 2022 year-over-year; TTM through Dec 2023 was $223.6 million, a 0.08% change, with the full-year FY2022 number at $223.8 million, changed N/A from a year prior.
Divestments hit $223.8 million in Q4 2022 for TherapeuticsMD, up from -$133000.0 in the prior quarter.
In the past five years, Divestments ranged from a high of $223.8 million in Q4 2022 to a low of -$119.8 million in Q2 2022.